Loading...

CANbridge Pharmaceuticals Inc.

1228.HK•HKSE
Healthcare
Biotechnology
HK$0.74
HK$0.06(8.82%)

CANbridge Pharmaceuticals Inc. (1228.HK) Stock Overview

Explore CANbridge Pharmaceuticals Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 65.5/100

Key Financials

Market Cap314.4M
P/E Ratio-0.65
EPS (TTM)$-1.14
ROE1.17%
Fundamental Analysis

AI Price Forecasts

1 Week$0.15
1 Month$0.16
3 Months$0.00
1 Year Target$0.09

1228.HK Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of CANbridge Pharmaceuticals Inc. (1228.HK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 84.49, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $0.09.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.65 and a market capitalization of 314.4M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

84.49RSI (14)
0.11MACD
58.64ADX
Stats data is not available for 1228.HKStats details for 1228.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for 1228.HKAnalyst Recommendations details for 1228.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Caphosol Mouth Rinse for temporary and persistent dryness of the mouth and throat. It also engages in the development of CAN008, an artificially engineered antibody-like fully human fusion protein for the treatment of glioblastoma multiforme; CAN108, an orally absorbed reversible inhibitor of the ileal bile acid transporter to treat rare cholestatic liver diseases; CAN106, a humanized monoclonal antibody against complement C5 being developed for the treatment of complement-mediated diseases; CAN103, a recombinant human enzyme replacement therapy (ERT); CAN104, a recombinant human ERT; CAN105, a bispecific antibody; CAN201, a gene therapy program that utilizes adeno-associated virus (AAV) sL65 capsid; and CAN202, a gene therapy program utilizing AAV sL65 capsid. The company was founded in 2012 and is headquartered in Beijing, China.

CEO

James Qun Xue

Employees

67

Headquarters

Timeloit, Beijing

Founded

2021

Frequently Asked Questions

;